Causes of death among patients with cutaneous melanoma: a US population-based study

被引:8
作者
Sadeq, Mohammed Ahmed [1 ]
Ashry, Mohamed Hady [2 ]
Ghorab, Reem Mohammed Farouk [1 ]
Afify, Abdelrahman Yousry [2 ]
机构
[1] Misr Univ Sci & Technol, Fac Med, Giza, Egypt
[2] New Giza Univ NGU, Sch Med, Giza, Egypt
关键词
IMMUNE CHECKPOINT INHIBITORS; TYPE-2; DIABETES-MELLITUS; INTERFERON-ALPHA; INTERLEUKIN-2; THERAPY; RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; MALIGNANT-MELANOMA; RISK; SURVIVAL; CANCER;
D O I
10.1038/s41598-023-37333-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Research on mortality outcomes and non-cancer-related causes of death in patients with cutaneous melanoma (CM) remains limited. This study aimed to identify the prevalence of non-cancer-related deaths following CM diagnosis. The data of 224,624 patients diagnosed with malignant CM in the United States between 2000 and 2019 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We stratified our cohort based on their melanoma stage at diagnosis and further calculated standardized mortality ratios (SMRs) for each cause of death, comparing their relative risk to that of the general US population. The total number of fatalities among melanoma patients was 60,110, representing 26.8% of the total cases. The percentage of deaths is directly proportional to the disease stage, reaching 80% in distant melanoma. The highest fatalities among the localized melanoma group (25,332; 60.5%) occurred from non-cancer causes, followed by melanoma-attributable deaths (10,817; 25.8%). Conversely, melanoma is the leading cause of death in regional and distant melanoma cohorts. Cardiovascular and cerebrovascular diseases were the most prevalent non-cancer causes of death among the three disease-stage cohorts. Compared to the general population, we did not observe an increased risk of death due to non-cancer causes in the localized CM cohort, while patients diagnosed with regional and distant CMs had a statistically significant higher risk of death from all the reported major causes of death.
引用
收藏
页数:11
相关论文
共 57 条
[1]   A central nervous system metastasis of melanoma with stroke-like onset of left-lower quadrantanopsia [J].
Arakawa, Akira ;
Mitsutake, Akihiko ;
Hideyama, Takuto ;
Sato, Tatsuya ;
Katsumata, Junko ;
Seki, Tomonari ;
Maekawa, Risa ;
Ohno, Makoto ;
Narita, Yoshitaka ;
Shiio, Yasushi .
JOURNAL OF GENERAL AND FAMILY MEDICINE, 2020, 21 (03) :77-79
[2]   Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J].
Ascierto, Paolo A. ;
McArthur, Grant A. ;
Dreno, Brigitte ;
Atkinson, Victoria ;
Liszkay, Gabrielle ;
Di Giacomo, Anna Maria ;
Mandala, Mario ;
Demidov, Lev ;
Stroyakovskiy, Daniil ;
Thomas, Luc ;
de la Cruz-Merino, Luis ;
Dutriaux, Caroline ;
Garbe, Claus ;
Yan, Yibing ;
Wongchenko, Matthew ;
Chang, Ilsung ;
Hsu, Jessie J. ;
Koralek, Daniel O. ;
Rooney, Isabelle ;
Ribas, Antoni ;
Larkin, James .
LANCET ONCOLOGY, 2016, 17 (09) :1248-1260
[3]   Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma [J].
Ashraf, Farhan ;
Marmoush, Fady ;
Shafi, Muhammad Ismail ;
Shah, Ashish .
CASE REPORTS IN CARDIOLOGY, 2016, 2016
[4]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[5]   Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis [J].
Berger, Mathilde ;
Amini-Adle, Mona ;
Maucort-Boulch, Delphine ;
Robinson, Philip ;
Thomas, Luc ;
Dalle, Stephane ;
Courand, Pierre-Yves .
CANCER MEDICINE, 2020, 9 (08) :2611-2620
[6]   Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors [J].
Bronte, Enrico ;
Bronte, Giuseppe ;
Novo, Giuseppina ;
Rinaldi, Gaetana ;
Bronte, Fabrizio ;
Passiglia, Francesco ;
Russo, Antonio .
PHARMACOLOGY & THERAPEUTICS, 2018, 192 :65-73
[7]   Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas [J].
Chen, Tianhui ;
Fallah, Mahdi ;
Foersti, Asta ;
Kharazmi, Elham ;
Sundquist, Kristina ;
Hemminki, Kari .
JAMA DERMATOLOGY, 2015, 151 (06) :607-615
[8]   Multiple primary (even in situ) melanomas in a patient pose significant risk to family members [J].
Chen, Tianhui ;
Hemminki, Kari ;
Kharazmi, Elham ;
Ji, Jianguang ;
Sundquist, Kristina ;
Fallah, Mahdi .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (15) :2659-2667
[9]   Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab [J].
Chokr, Nora ;
Farooq, Hafsa ;
Guadalupe, Elizabeth .
CASE REPORTS IN ONCOLOGICAL MEDICINE, 2018, 2018
[10]   Clinicopathological factors associated with death from thin (≤ 1•00 mm) melanoma [J].
Claeson, M. ;
Baade, P. ;
Brown, S. ;
Soyer, H. P. ;
Smithers, B. M. ;
Green, A. C. ;
Whiteman, D. C. ;
Khosrotehrani, K. .
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (04) :927-939